Literature DB >> 3264567

Effect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study.

A De Volder1, C J Sindic, A M Goffinet.   

Abstract

Sequential measurements of brain glucose metabolism were carried out in a patient with Wilson's disease, before and after successful treatment with D-penicillamine. They demonstrate an evolution of regional metabolism consistent with clinical improvement. The first study showed marked hypometabolism in the putamen on both sides. The second analysis showed bilateral improvement, with predominant residual deficits in the right putamen, while clinical symptoms of striatal dysfunction persisted on the left side. This observation suggests that positron emission tomography is able to follow the neurological evolution in cases of Wilson's disease.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3264567      PMCID： PMC1033199          DOI： 10.1136/jnnp.51.7.947

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  9 in total

1.  Penicillamine, a new oral therapy for Wilson's disease.

Authors:  J M WALSHE
Journal:  Am J Med       Date:  1956-10       Impact factor: 4.965

2.  Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients.

Authors:  T U Hoogenraad; J Van Hattum; C J Van den Hamer
Journal:  J Neurol Sci       Date:  1987-02       Impact factor: 3.181

3.  Prevention of Wilson's disease in asymptomatic patients.

Authors:  I Sternlieb; I H Scheinberg
Journal:  N Engl J Med       Date:  1968-02-15       Impact factor: 91.245

4.  Treatment of Wilson's disease.

Authors:  A Deiss
Journal:  Ann Intern Med       Date:  1983-09       Impact factor: 25.391

5.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method.

Authors:  M E Phelps; S C Huang; E J Hoffman; C Selin; L Sokoloff; D E Kuhl
Journal:  Ann Neurol       Date:  1979-11       Impact factor: 10.422

6.  Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.

Authors:  J M Walshe
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

7.  The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.

Authors:  I H Scheinberg; M E Jaffe; I Sternlieb
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  Oral zinc therapy for Wilson's disease.

Authors:  G J Brewer; G M Hill; A S Prasad; Z T Cossack; P Rabbani
Journal:  Ann Intern Med       Date:  1983-09       Impact factor: 25.391

9.  Wilson's disease studied with FDG and positron emission tomography.

Authors:  R A Hawkins; J C Mazziotta; M E Phelps
Journal:  Neurology       Date:  1987-11       Impact factor: 9.910
  9 in total
  7 in total

1.  Cranial MRI in Wilson's disease.

Authors:  L Prayer; D Wimberger; J Kramer; G Grimm; W Oder; H Imhof
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.

Authors:  W Oder; T Brücke; H Kollegger; J Spatt; S Asenbaum; L Deecke
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 3.  Neurologic impairment in Wilson disease.

Authors:  Petr Dusek; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

4.  Regional cerebral glucose consumption measured by positron emission tomography in patients with Wilson's disease.

Authors:  T Kuwert; H Hefter; D Scholz; M Milz; P Weiss; G Arendt; H Herzog; M Loken; M Hennerici; L E Feinendegen
Journal:  Eur J Nucl Med       Date:  1992

5.  Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease.

Authors:  G Schlaug; H Hefter; B Nebeling; V Engelbrecht; P Weiss; G Stöcklin; R J Seitz
Journal:  J Neurol       Date:  1994-10       Impact factor: 4.849

6.  Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration.

Authors:  C Hartard; B Weisner; C Dieu; K Kunze
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

7.  Relationship between striatal glucose consumption and copper excretion in patients with Wilson's disease treated with D-penicillamine.

Authors:  H Hefter; T Kuwert; H Herzog; G Arendt; W Stremmel; L E Feinendegen
Journal:  J Neurol       Date:  1993-11       Impact factor: 4.849
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.